Table of Content

1. Key Insights

2. Executive Summary of EGFR-NSCLC

3. SWOT Analysis of EGFR-NSCLC

4. EGFR-NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of EGFR-NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of EGFR-NSCLC in 2030: By Country

5. EGFR-Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total EGFR NSCLC cases in the United States
7.4.5. Total EGFR NSCLC Treated patient Pool in the United States

8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total EGFR NSCLC cases in Germany
8.1.5. Total EGFR NSCLC Treated patient Pool in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total EGFR NSCLC cases in France
8.2.5. Total EGFR NSCLC Treated patient Pool in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total EGFR NSCLC cases in Italy
8.3.5. Total EGFR NSCLC Treated patient Pool in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total EGFR NSCLC cases in Spain
8.4.5. Total EGFR NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total EGFR NSCLC cases in the United Kingdom
8.5.5. Total EGFR NSCLC Treated patient Pool in the United Kingdom

9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total EGFR NSCLC cases in Japan
9.1.5. Total EGFR NSCLC Treated patient Pool in Japan

10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of EGFR NSCLC

13. Key Endpoints in EGFR NSCLC Clinical Trials

14. Marketed Therapies
14.1. Key Cross
14.2. Tagrisso(Osimertinib): AstraZeneca
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.3. Vizimpro (Dacomitinib): Pfizer
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity

15. Emerging Therapies
15.1. Nazartinib (EGF816): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy
15.2. Capmatinib (INC280): Novartis Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.3.1. Product Description
15.3.2. Other Development Activity
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Safety and Efficacy
15.5. TAK-788: Takeda
15.5.1. Product Description
15.5.2. Clinical Development
15.5.3. Safety and Efficacy

16. EGFR-Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
16.1. Key Findings
16.2. Market Outlook: 7MM

17. EGFR Mutation?Market Size
17.1. Total Market Size of EGFR-positive NSCLC in the 7MM
17.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of EGFR NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of NSCLC in Japan

18. Market Access and Reimbursement of NSCLC Therapies

19. Market Drivers of NSCLC

20. Market Barriers of NSCLC
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight



List of Figures


Figure 1 EGFR NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total EGFR NSCLC cases in the United States
Figure 22 Total EGFR NSCLC Treated patient Pool in the United States
Figure 23 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 24 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 25 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 26 Total EGFR NSCLC cases in Germany
Figure 27 Total EGFR NSCLC Treated patient Pool in Germany
Figure 28 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 29 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 30 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 31 Total EGFR NSCLC cases in France
Figure 32 Total EGFR NSCLC Treated patient Pool in France
Figure 33 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 35 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 36 Total EGFR NSCLC cases in Italy
Figure 37 Total EGFR NSCLC Treated patient Pool in Italy
Figure 38 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 41 Total EGFR NSCLC cases in Spain
Figure 42 Total EGFR NSCLC Treated patient Pool in Spain
Figure 43 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 44 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 45 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 46 Total EGFR NSCLC cases in the United Kingdom
Figure 47 Total EGFR NSCLC Treated patient Pool in the United Kingdom
Figure 48 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 49 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 50 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 51 Total EGFR NSCLC cases in Japan
Figure 52 Total EGFR NSCLC Treated patient Pool in Japan
Figure 53 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 54 Timeline Illustrating the Development of Targeted Therapies and Immunotherapies for the Treatment of NSCLC Over two decades
Figure 55 Immune Checkpoint Inhibitor
Figure 56 Unmet Needs
Figure 57 Market Size of EGFR-positive NSCLC in the 7MM, in USD Million (2017–2030)
Figure 58 Market Size of EGFR-positive NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 59 Market Size of EGFR-positive NSCLC by therapies in the 7MM, in USD Million (2017–2030)
Figure 60 Market Size of EGFR-positive NSCLC in the US, USD Millions (2017–2030)
Figure 61 Market Size of EGFR-positive NSCLC in Germany, USD Millions (2017–2030)
Figure 62 Market Size of NSCLC in France, USD Millions (2017–2030)
Figure 63 Market Size of EGFR-positive NSCLC in Italy, USD Millions (2017–2030)
Figure 64 Market Size of EGFR-positive NSCLC in Spain, USD Millions (2017–2030)
Figure 65 Market Size of EGFR-positive NSCLC in the United Kingdom, IN USD Millions (2017–2030)
Figure 66 Market Size of NSCLC in Japan, USD Millions (2017–2030)
Figure 67 Market Drivers
Figure 68 Market Barriers

 

List of Tables


Table 1 Summary of EGFR NSCLC Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total EGFR NSCLC cases in the United States
Table 10 Total EGFR NSCLC Treated patient Pool in the United States
Table 11 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 12 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 13 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 14 Total EGFR NSCLC cases in Germany
Table 15 Total EGFR NSCLC Treated patient Pool in Germany
Table 16 Total Incident cases of NSCLC patients in France (2017–2030)
Table 17 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 18 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 19 Total EGFR NSCLC cases in France
Table 20 Total EGFR NSCLC Treated patient Pool in France
Table 21 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 23 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 24 Total EGFR NSCLC cases in Italy
Table 25 Total EGFR NSCLC Treated patient Pool in Italy
Table 26 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 29 Total EGFR NSCLC cases in Spain
Table 30 Total EGFR NSCLC Treated patient Pool in Spain
Table 31 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 32 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 33 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 34 Total EGFR NSCLC cases in the United Kingdom
Table 35 Total EGFR NSCLC Treated patient Pool in the United Kingdom
Table 36 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 37 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 38 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 39 Total EGFR NSCLC cases in Japan
Table 40 Total EGFR NSCLC Treated patient Pool in Japan
Table 41 Standard Treatment Options of NSCLC (Stage-wise)
Table 42 Summary of Recommendations (SEOM Clinical Guideline)
Table 43 Strength of Evidence
Table 44 Strength of Evidence
Table 45 Marketed Drugs Key Cross
Table 46 Standard Treatment Options of NSCLC (Stage-wise)
Table 47 Summary of Recommendations (SEOM Clinical Guideline)
Table 48 Strength of Evidence
Table 49 Strength of Evidence
Table 50 Marketed Drugs Key Cross
Table 51 Tagrisso (Osimertinib), Clinical Trial Description, 2020
Table 52 Vizimpro (Dacomitinib), Clinical Trial Description, 2020
Table 53 Nazartinib (EGF816), Clinical Trial Description, 2020
Table 54 Capmatinib (INC280), Clinical Trial Description, 2020
Table 55 JNJ-61186372 (JNJ-6372), Clinical Trial Description, 2020
Table 56 Lazertinib (YH25448), Clinical Trial Description, 2020
Table 57 TAK-788, Clinical Trial Description, 2020
Table 58 7MM Market Size of EGFR-positive NSCLC, in USD Million (2017–2030)
Table 59 7MM Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 60 7MM Market Size of EGFR-positive NSCLC by therapies in USD Million (2017–2030)
Table 61 United States Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 62 United States Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 63 Germany Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 64 Germany Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 65 France Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 66 France Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 67 Italy Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 68 Italy Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 69 Spain Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 70 Spain Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 71 United Kingdom Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 72 United Kingdom Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 73 Japan Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 74 Japan Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 75 National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies
Table 76 IQWiG Decisions for NSCLC Therapies
Table 77 Haute Autorit? de sant? (HAS) Decisions for NSCLC Therapies